Medical Technology

@xconomy.com 3 years ago

Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D

@xconomy.com 3 years ago

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

@xconomy.com 3 years ago

Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases

@xconomy.com 3 years ago

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

@xconomy.com 3 years ago

Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later

@xconomy.com 4 years ago

Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer

@xconomy.com 4 years ago

Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic

@xconomy.com 4 years ago

Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B

@xconomy.com 4 years ago

Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug

@xconomy.com 4 years ago

UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma

@xconomy.com 4 years ago

MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests

@xconomy.com 4 years ago

As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing

@xconomy.com 4 years ago

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

@xconomy.com 5 years ago

Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline

@xconomy.com 5 years ago

Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines